Reported Q: Q1 2025 Rev YoY: +27.2% EPS YoY: +42.3% Move: 0.00%
ResMed Inc
RSMDF
$28.10 0.00%
Exchange OTC Sector Healthcare Industry Medical Instruments Supplies
Q1 2025
Published: Oct 25, 2024

Company Status Snapshot

Fast view of the latest quarter outcome for RSMDF

Reported

Report Date

Oct 25, 2024

Quarter Q1 2025

Revenue

1.22B

YoY: +27.2%

EPS

2.11

YoY: +42.3%

Market Move

0.00%

Previous quarter: Q4 2024

Follow this company to get upcoming quarter alerts automatically.

Earnings Highlights

  • Revenue of $1.22B up 27.2% year-over-year
  • EPS of $2.11 increased by 42.3% from previous year
  • Gross margin of 58.6%
  • Net income of 311.36M
  • "" -
RSMDF
Company RSMDF

Executive Summary

ResMed Inc delivered a compelling QQ1 2025 performance, highlighted by a revenue rise of 27.15% year over year to $1.2245 billion and a solid margin profile. Gross profit reached $717.2 million with a gross margin of 58.57%, while operating income of $387.3 million produced an operating margin of 31.63%. Net income was $311.4 million, translating to EPS of $2.12 (diluted $2.11), underscoring meaningful operating leverage and favorable product mix. The company generated strong cash flow, with operating cash flow of $325.5 million and free cash flow of $305.9 million, supporting a net debt position of approximately $423.9 million on a cash balance of $426.4 million. In the balance sheet, total assets stood at about $7.22 billion, total liabilities at $2.03 billion, and total stockholdersโ€™ equity at $5.20 billion, reflecting a solid liquidity position and manageable leverage (debt to capitalization ~14.1%, interest coverage ~70x).

Segment composition remains supportive of long-duration growth: sustained demand for Sleep & Respiratory Care devices coupled with expanding Software as a Service (SaaS) platforms (Brightree, MatrixCare, HEALTHCAREfirst) that monetize care workflows and remote patient management. The qq1 results imply continued operating leverage as the company scales its high-margin SaaS offerings alongside hardware sales. Management commentary, though not disclosed in this transcript dataset, has historically emphasized ongoing R&D investment, international expansion, and cloud-based care coordination as key growth engines. Investors should monitor currency dynamics, reimbursement environments, and competitive intensity as the company scales its recurring-revenue mix.

Overall investment stance: ResMed demonstrates a resilient, margin-rich growth profile with abundant free cash flow and a prudent balance sheet. The QQ1 2025 metrics support a constructive longer-term view, driven by the combination of hardware demand in home-based therapy and expanding software-enabled care solutions.

Key Performance Indicators

Revenue
Increasing
1.22B
QoQ: 0.11% | YoY: 27.15%
Gross Profit
Increasing
717.22M
58.57% margin
QoQ: 1.84% | YoY: 19.52%
Operating Income
Increasing
387.31M
QoQ: 1.60% | YoY: 34.02%
Net Income
Increasing
311.36M
QoQ: 6.54% | YoY: 41.90%
EPS
Increasing
2.12
QoQ: 6.53% | YoY: 42.28%

Revenue Trend

Margin Analysis

Historical Earnings Comparison

PeriodRevenue ($M)EPS ($)YoY GrowthReport
Q1 2026 1,335.58 0.00 +9.2% View
Q3 2025 1,291.74 2.48 +7.9% View
Q2 2025 1,282.09 2.34 +10.3% View
Q1 2025 1,224.51 2.11 +27.2% View
Q4 2024 1,223.20 1.98 +9.0% View